Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 2276 - 2300 of 14994 in total
Human interferon beta (165 residues), cysteine 17 is substituted with serine. Produced in E. coli, no carbohydrates, MW=18.5kD
Approved
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... Intercellular Signaling Peptides and Proteins …
Rimonabant is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite. Rimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world. Rimonabant is approved...
Approved
Investigational
Matched Description: … Rimonabant is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. ... Rimonabant is approved in 38 countries including the E.U., Mexico, and Brazil. ... . advisory panel recommended the medicine not be approved because it may increase suicidal thinking and
Matched Categories: … Cannabinoids and similars ... Alimentary Tract and Metabolism ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Lepirudin is a recombinant hirudin formed by 65 amino acids that acts as a highly specific and direct thrombin inhibitor.[L41539,L41569] Natural hirudin is an endogenous anticoagulant found in Hirudo medicinalis leeches. Lepirudin is produced in yeast cells and is identical to natural hirudin except for the absence of sulfate on...
Approved
Withdrawn
Matched Description: … This activates endothelial cells and platelets and enhances the formation of thrombi. ... Lepirudin is a recombinant hirudin formed by 65 amino acids that acts as a highly specific and direct ... of sulfate on the tyrosine residue at position 63 and the substitution of leucine for isoleucine at …
Matched Categories: … Blood and Blood Forming Organs ... Amino Acids, Peptides, and Proteins …
Butoconazole is an imidazole antifungal used in gynecology.
Approved
Matched Categories: … Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …
Cystinosis is a rare disease caused by mutations in the CTNS gene that encodes for cystinosin, a protein responsible for transporting cystine out of the cell lysosome. A defect in cystinosin function is followed by cystine accumulation throughout the body, especially the eyes and kidneys. Several preparations of cysteamine exist...
Approved
Investigational
Matched Description: … in cystinosin function is followed by cystine accumulation throughout the body, especially the eyes and ... preparations of cysteamine exist for the treatment of cystinosis manifestations, some in capsule form, and ... L15616] In particular, cystine deposits on the eye can cause significant discomfort throughout the day and
Matched Categories: … Amino Acids and Derivatives ... Alimentary Tract and Metabolism …
Desirudin is a direct inhibitor of human thrombin. It has a protein structure that is similar to that of hirudin, the naturally occurring anticoagulant present in the peripharyngeal glands in the medicinal leech, Hirudo medicinalis. Hirudin is a single polypeptide chain of 65 amino acids residues and contains three disulfide...
Approved
Matched Description: … Hirudin is a single polypeptide chain of 65 amino acids residues and contains three disulfide bridges ... include: Bleeding gums, collection of blood under the skin, coughing up blood, deep, dark purple bruise and
Matched Categories: … Blood and Blood Forming Organs ... Amino Acids, Peptides, and Proteins …
A broad spectrum antimycotic with some action against Gram positive bacteria. It is used topically in dermatomycoses also orally and parenterally.
Approved
Matched Description: … It is used topically in dermatomycoses also orally and parenterally. …
Matched Categories: … Imidazole and Triazole Derivatives ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics ... Metabolic Side Effects of Drugs and Substances ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Human Rho(D) immune globulin is a medicine given by intramuscular or intravenous injection that is used to prevent the immunological condition known as Rh disease (or hemolytic disease of newborn). Rho (D) immune globulin is available as a sterile, lyophilized or liquid gamma globulin (IgG) fraction containing antibodies to the...
Approved
Investigational
Matched Description: … Immune globullin was purified via ion-exchange chromatography method and prepared from pools of human …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Immune Sera and Immunoglobulins …
Lanadelumab, also known as DX-2930, is a human IgG1 monoclonal antibody designed for subcutaneous self-injection. It is a fully human immunoglobulin, k-light-chain made in recombinant Chinese Hamster Ovary cells. It has been granted priority review, breakthrough therapy, and orphan drug designations for rare diseases based on the results of clinical...
Approved
Investigational
Matched Description: … [L4537] It has been granted priority review, breakthrough therapy, and orphan drug designations for rare ... hereditary angioedema by the FDA in August 2018,[L4537] followed by Health Canada in October 2018[L49226] and
Matched Categories: … Blood and Blood Forming Organs ... Amino Acids, Peptides, and Proteins …
Fluocortolone is a glucocorticoid with anti-inflammatory activity used topically for various skin disorders.
Approved
Withdrawn
Matched Categories: … Sex Hormones and Insulins ... fluocortolone and antibiotics ... fluocortolone and antiseptics ... fluocortolone and antiinfectives ... Hormones, Hormone Substitutes, and Hormone Antagonists …
A non-benzodiazepine that is used in the management of anxiety. It has been suggested for use in the treatment of muscle spasm.
Approved
Investigational
Withdrawn
Matched Categories: … Oxazol, Thiazine, and Triazine Derivatives …
The primary therapeutic use for which stem bromelain is currently and formally indicated is as a burn wound eschar debridement agent that has been approved by the EMA since 2012 and marketed under the brand name Nexobrid [FDA Label]. Bromelain itself belongs to a category of protein-digesting enzymes that are...
Approved
Investigational
Matched Description: … Although both fruit and stem bromelain are prepared differently and contain different enzymatic compositions ... The primary therapeutic use for which stem bromelain is currently and formally indicated is as a burn ... wound eschar debridement agent that has been approved by the EMA since 2012 and marketed under the brand …
Matched Categories: … Enzymes and Coenzymes …
Tofersen is under an intrathecally administered antisense oligonucleotide targeting the mutated SOD1 gene that causes amyotrophic lateral sclerosis (ALS). Although there were various causes of ALS, 2% of ALS cases are due to SOD1 mutations, with more than 200 SOD1 mutations documented.[A259028,A259033] Tofersen was granted accelerated approval from the FDA...
Approved
Investigational
Matched Description: … [A259023] However, it could potentially be due to the short timeframe of tofersen treatment, and more ... [L46133] Tofersen demonstrated efficacy in reducing the concentration of SOD1 in CSF and of neurofilament …
Matched Categories: … Nucleic Acids, Nucleotides, and Nucleosides …
Acarbose is a complex oligosaccharide that acts as an inhibitor of several enzymes responsible for the breakdown of complex carbohydrates in the intestines. It inhibits both pancreatic alpha-amylase and membrane-bound alpha-glucosidases - including intestinal glucoamylase, sucrase, maltase, and isomaltase - which are responsible for the metabolism of complex starches and...
Approved
Investigational
Matched Description: … starches and oligo-, tri-, and disaccharides into absorbable simple sugars. ... the subsequent postprandial increase in blood glucose and insulin levels. ... It inhibits both pancreatic alpha-amylase and membrane-bound alpha-glucosidases - including intestinal …
Matched Categories: … metformin and acarbose ... Alimentary Tract and Metabolism …
CD20, an antigen expressed by various B and T cells, is an attractive therapeutic target in various cancers and autoimmune conditions.[A244195, A244200, A244205] Monoclonal antibodies for B cell depletion rely on their binding affinity and ability to clear bound cells through mechanisms such as antibody-dependent cellular cytotoxicity (ADCC), mediated by...
Approved
Investigational
Matched Description: … and autoimmune conditions. ... CD20, an antigen expressed by various B and T cells, is an attractive therapeutic target in various cancers ... A244195, A244200, A244205] Monoclonal antibodies for B cell depletion rely on their binding affinity and
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Inappropriate growth of or self-directed antibody production by B-cells is the etiological underpinning of a variety of conditions, including the multiple sclerosis-like neurological condition neuromyelitis optica spectrum disorder (NMOSD).[A214283, A214286] Inebilizumab is a humanized afucosylated monoclonal IgG1 antibody directed against the broadly expressed B-cell surface antigen CD19. Inebilizumab is cytolytic,...
Approved
Investigational
Matched Description: … Inebilizumab is cytolytic, resulting in B-cell depletion and offering therapeutic benefit to patients ... [L14315] Given its mechanism of action and good safety profile, it may prove useful in the treatment …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Obinutuzumab is a humanized monoclonal antibody used as a combination treatment with chlorambucil to treat patients with untreated chronic lymphocytic leukemia. It was approved by the FDA in November 2013 and is marketed under the brand name Gazyva. There is a black box warning of fatal Hepatitis B Virus (HBV)...
Approved
Investigational
Matched Description: … It was approved by the FDA in November 2013 and is marketed under the brand name Gazyva. ... There is a black box warning of fatal Hepatitis B Virus (HBV) reactivation and fatal Progressive Multifocal …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Nivolumab is a fully human IgG4 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1). This antibody was produced entirely in mice and grafted onto human kappa and IgG4 Fc region with the mutation S228P for additional stability and reduced variability. It was developed by Bristol Myers Squibb. Nivolumab was...
Approved
Matched Description: … [L12129] This antibody was produced entirely in mice and grafted onto human kappa and IgG4 Fc region ... with the mutation _S228P_ for additional stability and reduced variability. …
Matched Categories: … nivolumab and relatlimab ... Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Teprotumumab is a fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor. Following a clinical trial in which its efficacy in the treatment of thyroid eye disease (TED) was assessed, it received "breakthrough therapy" designation from the FDA in 2016 and was approved by the FDA...
Approved
Investigational
Matched Description: … tissue remodeling behind the eye, and previous treatment options typically involved multiple invasive ... disease (TED) was assessed, it received "breakthrough therapy" designation from the FDA in 2016[A190129] and ... Thyroid eye disease is a potentially debilitating complication of Graves' Disease involving inflammation and
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Ravulizumab is a potent and selective complement 5 (C5) inhibitor. It is a humanized monoclonal IgG2/4 kappa antibody produced in Chinese hamster ovary (CHO) cells. Ravulizumab was engineered from eculizumab, another complement inhibitor, to increase the duration of action and reduce the frequency of drug administration. It works by blocking...
Approved
Investigational
Matched Description: … Ravulizumab is a potent and selective complement 5 (C5) inhibitor. ... atypical hemolytic uremic syndrome in children and adults. ... was engineered from [eculizumab], another complement inhibitor, to increase the duration of action and
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque psoriasis. By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders. Following its first global approval in Japan...
Approved
Matched Description: … in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and ... chronic inflammatory conditions, such as plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Drug-resistant bacteria, such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and penicillin-resistant Streptococcus penumoniae, represent a massive public health threat.[A199086, A199131] Tedizolid is a member of the oxazolidinone class of antibiotics, which includes the previously approved linezolid and is generally effective against multidrug-resistant Gram-positive bacteria. Tedizolid is indicated for the...
Approved
Matched Iupac: … 2-methyl-2H-1,2,3,4-tetrazol-5-yl)pyridin-3-yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl]methoxy}phosphonic acid
Matched Description: … ) and is generally more effective and more tolerable than [linezolid]. ... such as methicillin-resistant _Staphylococcus aureus_, vancomycin-resistant _Enterococcus faecium_, and ... member of the oxazolidinone class of antibiotics, which includes the previously approved [linezolid] and
Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, filgrastim. The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with with non-myeloid cancer receiving myelosuppressive anti-cancer treatment. Although the risk of developing febrile neutropenia...
Approved
Matched Description: … pharmacokinetic profile and conditions of use. ... than 20% in many readily used chemotherapy regimens,[A248855] infections pose risks of hospitalization and ... Pelmeg, Udenyca, Ziextenzo, Grasustek, Fylnetra, Stimufend) by Health Canada, European Union (EU), and
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... Intercellular Signaling Peptides and Proteins …
Tislelizumab is a humanized monoclonal IgG4 antibody against programmed death receptor-1 (PD-1). It was engineered to have a nullified Fc portion, thus minimizing binding to FcγR on macrophages and limiting treatment resistance via antibody-dependent phagocytosis. By blocking PD-L1/PD-L2–mediated cell signaling, tislelizumab restores T-cell function through cytokine production, resulting in immune-mediated...
Approved
Investigational
Matched Description: … It was engineered to have a nullified Fc portion, thus minimizing binding to FcγR on macrophages and ... [A262919] Tislelizumab is generally well tolerated with manageable and mild-to-moderate adverse effects …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Retifanlimab is a humanized IgG4 kappa monoclonal antibody that binds to the programmed death receptor-1 (PD-1), blocking PD-1 interaction with its ligands, programmed death-ligand 1 (PD-L1) and programmed death-ligand 2 (PD-L2). By blocking the PD-1/PD-L1/2 pathway, retifanlimab potentiates T-cell activity and boosts the immune response against cancer cells. Other monoclonal...
Approved
Investigational
Matched Description: … By blocking the PD-1/PD-L1/2 pathway, retifanlimab potentiates T-cell activity and boosts the immune ... death receptor-1 (PD-1), blocking PD-1 interaction with its ligands, programmed death-ligand 1 (PD-L1) and ... [L45603] Other monoclonal antibodies that block PD-1 include [pembrolizumab], [nivolumab] and [cemiplimab …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Displaying drugs 2276 - 2300 of 14994 in total